
Hongfu Cai

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4752578/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Cost-effectiveness of Osimertinib as First-line Treatment and Sequential Therapy for EGFR Mutation-positive Non-small Cell Lung Cancer in China. Clinical Therapeutics, 2019, 41, 280-290.	2.5	37
2	First-Line Durvalumab Plus Platinum-Etoposide Versus Platinum-Etoposide for Extensive-Stage Small-Cell Lung Cancer: A Cost-Effectiveness Analysis. Frontiers in Oncology, 2020, 10, 602185.	2.8	22
3	Cost-effectiveness analysis on binary/triple therapy on the basis of ixazomib or bortezomib for refractory or relapsed multiple myeloma. Leukemia and Lymphoma, 2019, 60, 2951-2959.	1.3	9
4	Cost-Effectiveness Analysis of Dacomitinib versus Gefitinib in the First-Line Treatment of EGFR-Positive Advanced or Metastatic Non-Small Cell Lung Cancer. Cancer Management and Research, 2021, Volume 13, 4263-4270.	1.9	6
5	Cost–effectiveness of second-line nivolumab for platinum-treated advanced non-small-cell lung cancer. Journal of Comparative Effectiveness Research, 2020, 9, 1301-1309.	1.4	3